Porton Pharma Solutions Ltd(300363) on January 16, the performance forecast for 2021 was released. It is estimated that the annual operating revenue of last year will reach 3.004 billion yuan to 3.108 billion yuan, an increase of 45% to 50% year-on-year; The net profit attributable to the parent company was 500 million yuan to 532 million yuan, with a year-on-year increase of 54% to 64%; The net profit after deducting non-profit was 519 million yuan to 548 million yuan, an increase of 80% to 90%.
It is reported that this is the third consecutive year of high performance growth of Porton Pharma Solutions Ltd(300363) since the strategic transformation of cdmo end-to-end one-stop service platform was deeply promoted in 2018 and entered the performance inflection point. In 2019, the company achieved an operating revenue of RMB 1.551 billion, a year-on-year increase of 30.93%; The net profit attributable to the parent company was 186 million yuan, a year-on-year increase of 49.04%; The net profit attributable to the parent company after deduction was 162 million yuan, an increase of 124.97%. In 2020, the company achieved a total operating revenue of 2.072 billion yuan, a year-on-year increase of 33.56%; The net profit attributable to the parent company was 324 million yuan, a year-on-year increase of 74.84%; The net profit attributable to the parent company after deducting non profits was 290 million yuan, an increase of 79.01%. For three consecutive years, the company’s net profit after deducting non profits increased by more than 70%.
Porton Pharma Solutions Ltd(300363) said that in 2021, under the background of the stable growth of global pharmaceutical R & D pipeline and the increasing trend of pharmaceutical R & D and production outsourcing, the company continued to expand and enrich product pipeline, continuously improved technical capacity, product delivery capacity and order acquisition capacity, and achieved significant growth in operating revenue; Meanwhile, with the further improvement of capacity utilization and operation efficiency, as well as the further optimization of product structure, the level of profitability continues to improve.
Last year, the two new business segments of the company’s preparation cdmo and gene cell therapy cdmo continued to “build capacity, build reputation and expand the market”, which was still in the loss stage as a whole, and the net profit attributable to the parent company in the consolidated statements was reduced by about 100 million yuan. In addition, the impact of the company’s non recurring profits and losses on the net profit during the reporting period was about – 7 million yuan, and 36.19 million yuan in 2020.
